Why did Maestro MEA users achieve the best data in the CiPA Phase II study? It's not by chance. Axion have designed the Maestro MEA platform to be the complete solution for MEA hiPSC-cardiomyocyte assays.
CiPA Myoctye Phase II: The Maestro Advantage Axion BioSystems
